Home/Filings/4/0001140361-25-006086
4//SEC Filing

Hopper Jonathan Mark 4

Accession 0001140361-25-006086

CIK 0000887359other

Filed

Feb 25, 7:00 PM ET

Accepted

Feb 26, 4:05 PM ET

Size

13.2 KB

Accession

0001140361-25-006086

Insider Transaction Report

Form 4
Period: 2025-02-24
Hopper Jonathan Mark
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-24+1,50066,737 total
  • Tax Payment

    Common Stock

    2025-02-24$52.33/sh636$33,28266,101 total
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-24+1,5009,000 total
    Common Stock (1,500 underlying)
  • Exercise/Conversion

    Common Stock

    2025-02-24+1,50065,237 total
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-24+1,50010,500 total
    Common Stock (1,500 underlying)
Footnotes (8)
  • [F1]The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.
  • [F2]The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 50% of the vested 3,000 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
  • [F3]These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
  • [F4]The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028, respectively.
  • [F5]These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
  • [F6]Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
  • [F7]No expiration date for this type of award.
  • [F8]The Fair Market Value of the vested derivative securities is $52.33 per share.

Issuer

Vericel Corp

CIK 0000887359

Entity typeother

Related Parties

1
  • filerCIK 0001626325

Filing Metadata

Form type
4
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 4:05 PM ET
Size
13.2 KB